-
1
-
-
0036692399
-
Recent evidence for dopamine abnormalities in schizophrenia
-
Abi-Dargham A. Recent evidence for dopamine abnormalities in schizophrenia. Eur. Psychiatry 17 (2002) 341-347
-
(2002)
Eur. Psychiatry
, vol.17
, pp. 341-347
-
-
Abi-Dargham, A.1
-
3
-
-
1842523130
-
Do we still believe in the dopamine hypothesis? New data bring new evidence
-
Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 7 Suppl. 1 (2004) S1-S5
-
(2004)
Int. J. Neuropsychopharmacol.
, vol.7
, Issue.SUPPL. 1
-
-
Abi-Dargham, A.1
-
4
-
-
33847345013
-
Alterations of serotonin transmission in schizophrenia
-
Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int. Rev. Neurobiol. 78 (2007) 133-164
-
(2007)
Int. Rev. Neurobiol.
, vol.78
, pp. 133-164
-
-
Abi-Dargham, A.1
-
5
-
-
0012918167
-
Serotonin
-
Cheney D., Davis K.L., Coyle J.T., and Nemeroff C. (Eds), Williams & Wilkins, New York, NY
-
Aghajanian G.K., and Sanders-Bush E. Serotonin. In: Cheney D., Davis K.L., Coyle J.T., and Nemeroff C. (Eds). Neuropsychopharmacology: The Fifth Generation of Progress (2002), Williams & Wilkins, New York, NY 15-34
-
(2002)
Neuropsychopharmacology: The Fifth Generation of Progress
, pp. 15-34
-
-
Aghajanian, G.K.1
Sanders-Bush, E.2
-
6
-
-
33846426067
-
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
-
Alex K.D., and Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 113 (2007) 296-320
-
(2007)
Pharmacol. Ther.
, vol.113
, pp. 296-320
-
-
Alex, K.D.1
Pehek, E.A.2
-
8
-
-
0004235298
-
-
American Psychiatric Association, American Psychiatric Association, Washington, DC
-
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn.) (1994), American Psychiatric Association, Washington, DC
-
(1994)
Diagnostic and Statistical Manual of Mental Disorders (4th edn.)
-
-
-
9
-
-
0028871474
-
Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system
-
Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathe J.M., and Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn Schmiedebergs Arch. Pharmacol. 352 (1995) 374-385
-
(1995)
Naunyn Schmiedebergs Arch. Pharmacol.
, vol.352
, pp. 374-385
-
-
Andersson, J.L.1
Nomikos, G.G.2
Marcus, M.3
Hertel, P.4
Mathe, J.M.5
Svensson, T.H.6
-
10
-
-
0027199189
-
(R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex
-
Arborelius L., Nomikos G.G., Hacksell U., and Svensson T.H. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol. Scand. 148 (1993) 465-466
-
(1993)
Acta Physiol. Scand.
, vol.148
, pp. 465-466
-
-
Arborelius, L.1
Nomikos, G.G.2
Hacksell, U.3
Svensson, T.H.4
-
11
-
-
0023033230
-
Further studies of the mechanisms behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats
-
Arnt J.H.J., and Bach-Lauritsen T. Further studies of the mechanisms behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol. Toxicol. (Copenh) 59 (1986) 319-324
-
(1986)
Acta Pharmacol. Toxicol. (Copenh)
, vol.59
, pp. 319-324
-
-
Arnt, J.H.J.1
Bach-Lauritsen, T.2
-
13
-
-
0023873890
-
Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses
-
Baldessarini R.J., Cohen B.M., and Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 45 (1988) 79-91
-
(1988)
Arch. Gen. Psychiatry
, vol.45
, pp. 79-91
-
-
Baldessarini, R.J.1
Cohen, B.M.2
Teicher, M.H.3
-
14
-
-
0018647518
-
Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy
-
Balsara J.J., Jadhav J.H., and Chandorkar A.G. Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology (Berl.) 62 (1979) 67-69
-
(1979)
Psychopharmacology (Berl.)
, vol.62
, pp. 67-69
-
-
Balsara, J.J.1
Jadhav, J.H.2
Chandorkar, A.G.3
-
18
-
-
0842264904
-
The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice
-
Barr A.M., Lehmann-Masten V., Paulus M., Gainetdinov R.R., Caron M.G., and Geyer M.A. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 29 (2004) 221-228
-
(2004)
Neuropsychopharmacology
, vol.29
, pp. 221-228
-
-
Barr, A.M.1
Lehmann-Masten, V.2
Paulus, M.3
Gainetdinov, R.R.4
Caron, M.G.5
Geyer, M.A.6
-
19
-
-
33747053349
-
Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats
-
Barr A.M., Powell S.B., Markou A., and Geyer M.A. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 51 (2006) 457-465
-
(2006)
Neuropharmacology
, vol.51
, pp. 457-465
-
-
Barr, A.M.1
Powell, S.B.2
Markou, A.3
Geyer, M.A.4
-
20
-
-
34548158648
-
Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia?
-
Bender S., Weisbrod M., and Resch F. Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia?. J. Neural Transm. 114 (2007) 1199-1215
-
(2007)
J. Neural Transm.
, vol.114
, pp. 1199-1215
-
-
Bender, S.1
Weisbrod, M.2
Resch, F.3
-
22
-
-
34548160607
-
Social cognitive impairments in first episode psychosis
-
Bertrand M.C., Sutton H., Achim A.M., Malla A.K., and Lepage M. Social cognitive impairments in first episode psychosis. Schizophr. Res. 95 (2007) 124-133
-
(2007)
Schizophr. Res.
, vol.95
, pp. 124-133
-
-
Bertrand, M.C.1
Sutton, H.2
Achim, A.M.3
Malla, A.K.4
Lepage, M.5
-
23
-
-
33645242661
-
The structure of negative symptoms within schizophrenia: implications for assessment
-
Blanchard J.J., and Cohen A.S. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr. Bull. 32 (2006) 238-245
-
(2006)
Schizophr. Bull.
, vol.32
, pp. 238-245
-
-
Blanchard, J.J.1
Cohen, A.S.2
-
26
-
-
28044457735
-
The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity
-
Bortolozzi A., Diaz-Mataix L., Scorza M.C., Celada P., and Artigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J. Neurochem. 95 (2005) 1597-1607
-
(2005)
J. Neurochem.
, vol.95
, pp. 1597-1607
-
-
Bortolozzi, A.1
Diaz-Mataix, L.2
Scorza, M.C.3
Celada, P.4
Artigas, F.5
-
27
-
-
0025190458
-
Sensorimotor gating and schizophrenia. Human and animal model studies
-
Braff D.L., and Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47 (1990) 181-188
-
(1990)
Arch. Gen. Psychiatry
, vol.47
, pp. 181-188
-
-
Braff, D.L.1
Geyer, M.A.2
-
28
-
-
0028855452
-
Serotonin, schizophrenia and antipsychotic drug action
-
Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res. 14 (1995) 187-202
-
(1995)
Schizophr. Res.
, vol.14
, pp. 187-202
-
-
Breier, A.1
-
31
-
-
33846297688
-
Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac?
-
Buckley P.F., and Stahl S.M. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac?. Acta Psychiatr. Scand. 115 (2007) 93-100
-
(2007)
Acta Psychiatr. Scand.
, vol.115
, pp. 93-100
-
-
Buckley, P.F.1
Stahl, S.M.2
-
33
-
-
33646152528
-
A dopaminergic deficit hypothesis of schizophrenia: the path to discovery
-
Carlsson A., and Carlsson M.L. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin. Neurosci. 8 (2006) 137-142
-
(2006)
Dialogues Clin. Neurosci.
, vol.8
, pp. 137-142
-
-
Carlsson, A.1
Carlsson, M.L.2
-
35
-
-
78651116398
-
Effect of chlorpromazine or haloperidol on formation of 3-methoxy-tyramine and normetanephrine in mouse brain
-
Carlsson A.L.M. Effect of chlorpromazine or haloperidol on formation of 3-methoxy-tyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20 (1963) 140-144
-
(1963)
Acta Pharmacol. Toxicol.
, vol.20
, pp. 140-144
-
-
Carlsson, A.L.M.1
-
36
-
-
38449084949
-
Challenge to atypical antipsychotic drug effect on cognition
-
Carpenter Jr. W.T., and Conley R.R. Challenge to atypical antipsychotic drug effect on cognition. Am. J. Psychiatry 164 (2007) 1910-1911
-
(2007)
Am. J. Psychiatry
, vol.164
, pp. 1910-1911
-
-
Carpenter Jr., W.T.1
Conley, R.R.2
-
38
-
-
0025824232
-
Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics
-
Casey D.E. Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacol. Bull. 27 (1991) 47-50
-
(1991)
Psychopharmacol. Bull.
, vol.27
, pp. 47-50
-
-
Casey, D.E.1
-
39
-
-
0021943587
-
Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone
-
Ceulemans D.L., Gelders Y.G., Hoppenbrouwers M.L., Reyntjens A.J., and Janssen P.A. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology (Berl.) 85 (1985) 329-332
-
(1985)
Psychopharmacology (Berl.)
, vol.85
, pp. 329-332
-
-
Ceulemans, D.L.1
Gelders, Y.G.2
Hoppenbrouwers, M.L.3
Reyntjens, A.J.4
Janssen, P.A.5
-
40
-
-
0027475985
-
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
-
Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., and Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13 (1993) 25-40
-
(1993)
J. Clin. Psychopharmacol.
, vol.13
, pp. 25-40
-
-
Chouinard, G.1
Jones, B.2
Remington, G.3
Bloom, D.4
Addington, D.5
MacEwan, G.W.6
Labelle, A.7
Beauclair, L.8
Arnott, W.9
-
41
-
-
0029020015
-
The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine
-
Cools A.R., Prinssen E.P., and Ellenbroek B.A. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacology (Berl.) 119 (1995) 428-439
-
(1995)
Psychopharmacology (Berl.)
, vol.119
, pp. 428-439
-
-
Cools, A.R.1
Prinssen, E.P.2
Ellenbroek, B.A.3
-
42
-
-
1542373740
-
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
-
Correll C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161 (2004) 414-425
-
(2004)
Am. J. Psychiatry
, vol.161
, pp. 414-425
-
-
Correll, C.U.1
Leucht, S.2
Kane, J.M.3
-
44
-
-
0019139272
-
Positive and negative schizophrenic symptoms and the role of dopamine
-
Crow T.J. Positive and negative schizophrenic symptoms and the role of dopamine. Br. J. Psychiatry 137 (1980) 383-386
-
(1980)
Br. J. Psychiatry
, vol.137
, pp. 383-386
-
-
Crow, T.J.1
-
45
-
-
0017727653
-
The nucleus accumbens - possible site of antipsychotic action of neuroleptic drugs?
-
Crow T.J., Deakin J.F., and Longden A. The nucleus accumbens - possible site of antipsychotic action of neuroleptic drugs?. Psychol. Med. 7 (1977) 213-221
-
(1977)
Psychol. Med.
, vol.7
, pp. 213-221
-
-
Crow, T.J.1
Deakin, J.F.2
Longden, A.3
-
46
-
-
0018239823
-
Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat
-
Davies J., and Tongroach P. Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur. J. Pharmacol. 51 (1978) 91-100
-
(1978)
Eur. J. Pharmacol.
, vol.51
, pp. 91-100
-
-
Davies, J.1
Tongroach, P.2
-
48
-
-
0032817813
-
2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation
-
2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 73 (1999) 1033-1042
-
(1999)
J. Neurochem.
, vol.73
, pp. 1033-1042
-
-
De Deurwaerdere, P.1
Spampinato, U.2
-
49
-
-
24944508126
-
Subjective experiences during dopamine depletion
-
de Haan L., Booij J., Lavalye J., van Amelsvoort T., and Linszen D. Subjective experiences during dopamine depletion. Am. J. Psychiatry 162 (2005) 1755
-
(2005)
Am. J. Psychiatry
, vol.162
, pp. 1755
-
-
de Haan, L.1
Booij, J.2
Lavalye, J.3
van Amelsvoort, T.4
Linszen, D.5
-
51
-
-
0037313398
-
2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study
-
2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am. J. Psychiatry 160 (2003) 303-309
-
(2003)
Am. J. Psychiatry
, vol.160
, pp. 303-309
-
-
de Haan, L.1
van Bruggen, M.2
Lavalaye, J.3
Booij, J.4
Dingemans, P.M.5
Linszen, D.6
-
52
-
-
0033956968
-
1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin on spontaneous activity, cocaine-induced hyperactivity and behavioral sensitization: a microanalysis of locomotor activity
-
1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin on spontaneous activity, cocaine-induced hyperactivity and behavioral sensitization: a microanalysis of locomotor activity. J. Pharmacol. Exp. Ther. 292 (2000) 610-617
-
(2000)
J. Pharmacol. Exp. Ther.
, vol.292
, pp. 610-617
-
-
De La Garza II, R.1
Cunningham, K.A.2
-
53
-
-
0024543628
-
From chlorpromazine to tardive dyskinesia (brief history of neuroleptics)
-
Deniker P. From chlorpromazine to tardive dyskinesia (brief history of neuroleptics). Psychiatr. J. Univ. Ottawa 14 (1989) 253-259
-
(1989)
Psychiatr. J. Univ. Ottawa
, vol.14
, pp. 253-259
-
-
Deniker, P.1
-
54
-
-
0025163692
-
The neuroleptics: a historical survey
-
Deniker P. The neuroleptics: a historical survey. Acta Physiol. Scand. 82 (1990) 83-87
-
(1990)
Acta Physiol. Scand.
, vol.82
, pp. 83-87
-
-
Deniker, P.1
-
55
-
-
0025924508
-
2 receptor antagonist, ritanserin, on biogenic amines in the rat nucleus accumbens
-
2 receptor antagonist, ritanserin, on biogenic amines in the rat nucleus accumbens. Eur. J. Pharmacol. 192 (1991) 427-429
-
(1991)
Eur. J. Pharmacol.
, vol.192
, pp. 427-429
-
-
Devaud, L.L.1
Hollingsworth, E.B.2
-
56
-
-
0028847715
-
Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis
-
Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., Pappas N., Brodie J.D., and Ashby Jr. C.R. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 15 (1995) 821-829
-
(1995)
J. Neurosci.
, vol.15
, pp. 821-829
-
-
Dewey, S.L.1
Smith, G.S.2
Logan, J.3
Alexoff, D.4
Ding, Y.S.5
King, P.6
Pappas, N.7
Brodie, J.D.8
Ashby Jr., C.R.9
-
61
-
-
37549046758
-
Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action
-
Di Pietro N.C., and Seamans J.K. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 40 Suppl. 1 (2007) S27-S33
-
(2007)
Pharmacopsychiatry
, vol.40
, Issue.SUPPL. 1
-
-
Di Pietro, N.C.1
Seamans, J.K.2
-
63
-
-
0027490544
-
2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial
-
2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br. J. Psychiatry 163 (1993) 451-455
-
(1993)
Br. J. Psychiatry
, vol.163
, pp. 451-455
-
-
Duinkerke, S.J.1
Botter, P.A.2
Jansen, A.A.3
van Dongen, P.A.4
van Haaften, A.J.5
Boom, A.J.6
van Laarhoven, J.H.7
Busard, H.L.8
-
64
-
-
34248534333
-
Insights into the role of dopamine receptor systems in learning and memory
-
El-Ghundi M., O'Dowd B.F., and George S.R. Insights into the role of dopamine receptor systems in learning and memory. Rev. Neurosci. 18 (2007) 37-66
-
(2007)
Rev. Neurosci.
, vol.18
, pp. 37-66
-
-
El-Ghundi, M.1
O'Dowd, B.F.2
George, S.R.3
-
66
-
-
0023860186
-
The paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism
-
Ellenbroek B., and Cools A.R. The paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci. 42 (1988) 1205-1213
-
(1988)
Life Sci.
, vol.42
, pp. 1205-1213
-
-
Ellenbroek, B.1
Cools, A.R.2
-
67
-
-
0000683636
-
Animal models with construct validity for schizophrenia
-
Ellenbroek B.A., and Cools A.R. Animal models with construct validity for schizophrenia. Behav. Pharmacol. 1 (1990) 469-490
-
(1990)
Behav. Pharmacol.
, vol.1
, pp. 469-490
-
-
Ellenbroek, B.A.1
Cools, A.R.2
-
68
-
-
0030272376
-
Activity of "seroquel" (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine
-
Ellenbroek B.A., Lubbers L.J., and Cools A.R. Activity of "seroquel" (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 15 (1996) 406-416
-
(1996)
Neuropsychopharmacology
, vol.15
, pp. 406-416
-
-
Ellenbroek, B.A.1
Lubbers, L.J.2
Cools, A.R.3
-
69
-
-
0023634681
-
The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs
-
Ellenbroek B.A., Peeters B.W., Honig W.M., and Cools A.R. The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology (Berl.) 93 (1987) 343-348
-
(1987)
Psychopharmacology (Berl.)
, vol.93
, pp. 343-348
-
-
Ellenbroek, B.A.1
Peeters, B.W.2
Honig, W.M.3
Cools, A.R.4
-
70
-
-
0028006302
-
The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats
-
Ellenbroek B.A., Prinssen E.P., and Cools A.R. The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur. J. Neurosci. 6 (1994) 1-8
-
(1994)
Eur. J. Neurosci.
, vol.6
, pp. 1-8
-
-
Ellenbroek, B.A.1
Prinssen, E.P.2
Cools, A.R.3
-
71
-
-
15744364142
-
2C receptor and olanzapine
-
2C receptor and olanzapine. Am. J. Med. Genet B Neuropsychiatr. Genet. 134 (2005) 76-78
-
(2005)
Am. J. Med. Genet B Neuropsychiatr. Genet.
, vol.134
, pp. 76-78
-
-
Ellingrod, V.L.1
Perry, P.J.2
Ringold, J.C.3
Lund, B.C.4
Bever-Stille, K.5
Fleming, F.6
Holman, T.L.7
Miller, D.8
-
74
-
-
33644850948
-
Serotonin-dopamine interaction as a focus of novel antidepressant drugs
-
Esposito E. Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr. Drug Targets 7 (2006) 177-185
-
(2006)
Curr. Drug Targets
, vol.7
, pp. 177-185
-
-
Esposito, E.1
-
75
-
-
33846305060
-
Effectiveness of switching antipsychotic medications
-
Essock S.M., Covell N.H., Davis S.M., Stroup T.S., Rosenheck R.A., and Lieberman J.A. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry 163 (2006) 2090-2095
-
(2006)
Am. J. Psychiatry
, vol.163
, pp. 2090-2095
-
-
Essock, S.M.1
Covell, N.H.2
Davis, S.M.3
Stroup, T.S.4
Rosenheck, R.A.5
Lieberman, J.A.6
-
77
-
-
37549064027
-
5-HT receptor regulation of neurotransmitter release
-
Fink K.B., and Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol. Rev. 59 (2007) 360-417
-
(2007)
Pharmacol. Rev.
, vol.59
, pp. 360-417
-
-
Fink, K.B.1
Gothert, M.2
-
78
-
-
0023630323
-
2 receptors throughout the rat central nervous system using quantitative autoradiography
-
2 receptors throughout the rat central nervous system using quantitative autoradiography. Brain Res. 421 (1987) 263-279
-
(1987)
Brain Res.
, vol.421
, pp. 263-279
-
-
Fischette, C.T.1
Nock, B.2
Renner, K.3
-
79
-
-
0031005967
-
Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes
-
Fleischhacker W.W., and Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 53 (1997) 915-929
-
(1997)
Drugs
, vol.53
, pp. 915-929
-
-
Fleischhacker, W.W.1
Hummer, M.2
-
80
-
-
0018687161
-
The influence of cerebral 5-hydroxytryptamine on catalepsy induced by brain-amine depleting neuroleptics or by cholinomimetics
-
Fuenmayor L.D., and Vogt M. The influence of cerebral 5-hydroxytryptamine on catalepsy induced by brain-amine depleting neuroleptics or by cholinomimetics. Br. J. Pharmacol. 67 (1979) 309-318
-
(1979)
Br. J. Pharmacol.
, vol.67
, pp. 309-318
-
-
Fuenmayor, L.D.1
Vogt, M.2
-
81
-
-
0001902397
-
Drugs antagonistic to 5-hydroxytryptamine
-
Wolstenholme G. (Ed), Little Brown and Co., Boston, MA
-
Gaddum J. Drugs antagonistic to 5-hydroxytryptamine. In: Wolstenholme G. (Ed). Ciba Foundation Symposium on Hypertension (1954), Little Brown and Co., Boston, MA 75-77
-
(1954)
Ciba Foundation Symposium on Hypertension
, pp. 75-77
-
-
Gaddum, J.1
-
82
-
-
40949136198
-
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review
-
Gao K., Kemp D.E., Ganocy S.J., Gajwani P., Xia G., and Calabrese J.R. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J. Clin. Psychopharmacol. 28 (2008) 203-209
-
(2008)
J. Clin. Psychopharmacol.
, vol.28
, pp. 203-209
-
-
Gao, K.1
Kemp, D.E.2
Ganocy, S.J.3
Gajwani, P.4
Xia, G.5
Calabrese, J.R.6
-
83
-
-
34547118579
-
2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models
-
2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J. Pharmacol. Exp. Ther. 322 (2007) 862-870
-
(2007)
J. Pharmacol. Exp. Ther.
, vol.322
, pp. 862-870
-
-
Gardell, L.R.1
Vanover, K.E.2
Pounds, L.3
Johnson, R.W.4
Barido, R.5
Anderson, G.T.6
Veinbergs, I.7
Dyssegaard, A.8
Brunmark, P.9
Tabatabaei, A.10
Davis, R.E.11
Brann, M.R.12
Hacksell, U.13
Bonhaus, D.W.14
-
84
-
-
0034598111
-
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
-
Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
-
(2000)
BMJ
, vol.321
, pp. 1371-1376
-
-
Geddes, J.1
Freemantle, N.2
Harrison, P.3
Bebbington, P.4
-
85
-
-
0024366801
-
Thymosthenic agents, a novel approach in the treatment of schizophrenia
-
Gelders Y.G. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br. J. Psychiatry 155 Suppl. (1989) 33-36
-
(1989)
Br. J. Psychiatry
, vol.155
, Issue.SUPPL
, pp. 33-36
-
-
Gelders, Y.G.1
-
86
-
-
0022414990
-
The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form
-
George S.R., Watanabe M., Di Paolo T., Falardeau P., Labrie F., and Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 117 (1985) 690-697
-
(1985)
Endocrinology
, vol.117
, pp. 690-697
-
-
George, S.R.1
Watanabe, M.2
Di Paolo, T.3
Falardeau, P.4
Labrie, F.5
Seeman, P.6
-
87
-
-
0029987475
-
6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats
-
6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 23 (1996) 164-173
-
(1996)
Synapse
, vol.23
, pp. 164-173
-
-
Gerard, C.1
el Mestikawy, S.2
Lebrand, C.3
Adrien, J.4
Ruat, M.5
Traiffort, E.6
Hamon, M.7
Martres, M.P.8
-
88
-
-
0030614562
-
6 receptor-like material in the rat central nervous system
-
6 receptor-like material in the rat central nervous system. Brain Res. 746 (1997) 207-219
-
(1997)
Brain Res.
, vol.746
, pp. 207-219
-
-
Gerard, C.1
Martres, M.P.2
Lefevre, K.3
Miquel, M.C.4
Verge, D.5
Lanfumey, L.6
Doucet, E.7
Hamon, M.8
el Mestikawy, S.9
-
89
-
-
33947507311
-
The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps?
-
Geyer M.A. The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps?. Neurotox. Res. 10 (2006) 211-220
-
(2006)
Neurotox. Res.
, vol.10
, pp. 211-220
-
-
Geyer, M.A.1
-
90
-
-
0345690103
-
Animal behavior models of the mechanisms underlying antipsychotic atypicality
-
Geyer M.A., and Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1071-1079
-
(2003)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.27
, pp. 1071-1079
-
-
Geyer, M.A.1
Ellenbroek, B.2
-
91
-
-
0018248907
-
Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system: comparison of injection sites
-
Giambalvo C.T., and Snodgrass S.R. Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system: comparison of injection sites. Brain Res. 152 (1978) 555-566
-
(1978)
Brain Res.
, vol.152
, pp. 555-566
-
-
Giambalvo, C.T.1
Snodgrass, S.R.2
-
92
-
-
0027533244
-
Recent advances in the molecular biology of dopamine receptors
-
Gingrich J.A., and Caron M.G. Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16 (1993) 299-321
-
(1993)
Annu. Rev. Neurosci.
, vol.16
, pp. 299-321
-
-
Gingrich, J.A.1
Caron, M.G.2
-
93
-
-
0003022152
-
Serotonin receptor subtypes and ligands
-
Bloom F.E., and Kupfer D. (Eds), Williams & Wilkins, New York, NY
-
Glennon R.A., Dukat M., and Westkaemper R.B. Serotonin receptor subtypes and ligands. In: Bloom F.E., and Kupfer D. (Eds). Neuropsychopharmacology: The Fourth Generation of Progress (1995), Williams & Wilkins, New York, NY 415-429
-
(1995)
Neuropsychopharmacology: The Fourth Generation of Progress
, pp. 415-429
-
-
Glennon, R.A.1
Dukat, M.2
Westkaemper, R.B.3
-
94
-
-
34948816016
-
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
-
Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., and Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 64 (2007) 1115-1122
-
(2007)
Arch. Gen. Psychiatry
, vol.64
, pp. 1115-1122
-
-
Goldberg, T.E.1
Goldman, R.S.2
Burdick, K.E.3
Malhotra, A.K.4
Lencz, T.5
Patel, R.C.6
Woerner, M.G.7
Schooler, N.R.8
Kane, J.M.9
Robinson, D.G.10
-
96
-
-
33847400445
-
The dopamine system and the pathophysiology of schizophrenia: a basic science perspective
-
Goto Y., and Grace A.A. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective. Int. Rev. Neurobiol. 78 (2007) 41-68
-
(2007)
Int. Rev. Neurobiol.
, vol.78
, pp. 41-68
-
-
Goto, Y.1
Grace, A.A.2
-
97
-
-
0026059697
-
Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia
-
Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
-
(1991)
Neuroscience
, vol.41
, pp. 1-24
-
-
Grace, A.A.1
-
98
-
-
0021718376
-
The control of firing pattern in nigral dopamine neurons: burst firing
-
Grace A.A., and Bunney B.S. The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci. 4 (1984) 2877-2890
-
(1984)
J. Neurosci.
, vol.4
, pp. 2877-2890
-
-
Grace, A.A.1
Bunney, B.S.2
-
99
-
-
0021714346
-
The control of firing pattern in nigral dopamine neurons: single spike firing
-
Grace A.A., and Bunney B.S. The control of firing pattern in nigral dopamine neurons: single spike firing. J. Neurosci. 4 (1984) 2866-2876
-
(1984)
J. Neurosci.
, vol.4
, pp. 2866-2876
-
-
Grace, A.A.1
Bunney, B.S.2
-
101
-
-
34548348729
-
Molecular targets for treating cognitive dysfunction in schizophrenia
-
Gray J.A., and Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull. 33 (2007) 1100-1119
-
(2007)
Schizophr. Bull.
, vol.33
, pp. 1100-1119
-
-
Gray, J.A.1
Roth, B.L.2
-
102
-
-
0029918481
-
What are the functional consequences of neurocognitive deficits in schizophrenia?
-
Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153 (1996) 321-330
-
(1996)
Am. J. Psychiatry
, vol.153
, pp. 321-330
-
-
Green, M.F.1
-
103
-
-
0037097453
-
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone
-
Green M.F., Marder S.R., Glynn S.M., McGurk S.R., Wirshing W.C., Wirshing D.A., Liberman R.P., and Mintz J. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry 51 (2002) 972-978
-
(2002)
Biol. Psychiatry
, vol.51
, pp. 972-978
-
-
Green, M.F.1
Marder, S.R.2
Glynn, S.M.3
McGurk, S.R.4
Wirshing, W.C.5
Wirshing, D.A.6
Liberman, R.P.7
Mintz, J.8
-
104
-
-
7544250144
-
The MATRICS initiative: developing a consensus cognitive battery for clinical trials
-
Green M.F., and Nuechterlein K.H. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr. Res. 72 (2004) 1-3
-
(2004)
Schizophr. Res.
, vol.72
, pp. 1-3
-
-
Green, M.F.1
Nuechterlein, K.H.2
-
105
-
-
26444444254
-
Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy
-
Greenwood K.E., Landau S., and Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr. Bull. 31 (2005) 910-921
-
(2005)
Schizophr. Bull.
, vol.31
, pp. 910-921
-
-
Greenwood, K.E.1
Landau, S.2
Wykes, T.3
-
107
-
-
4644250170
-
Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders
-
Gupta S., and Masand P. Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders. Ann. Clin. Psychiatry 16 (2004) 155-166
-
(2004)
Ann. Clin. Psychiatry
, vol.16
, pp. 155-166
-
-
Gupta, S.1
Masand, P.2
-
108
-
-
6344253360
-
Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management
-
Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
-
(2004)
Drugs
, vol.64
, pp. 2291-2314
-
-
Haddad, P.M.1
Wieck, A.2
-
109
-
-
26444457491
-
Predicting drug efficacy for cognitive deficits in schizophrenia
-
Hagan J.J., and Jones D.N. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr. Bull. 31 (2005) 830-853
-
(2005)
Schizophr. Bull.
, vol.31
, pp. 830-853
-
-
Hagan, J.J.1
Jones, D.N.2
-
111
-
-
33645230162
-
Negative symptoms and cognitive deficits: what is the nature of their relationship?
-
Harvey P.D., Koren D., Reichenberg A., and Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr. Bull. 32 (2006) 250-258
-
(2006)
Schizophr. Bull.
, vol.32
, pp. 250-258
-
-
Harvey, P.D.1
Koren, D.2
Reichenberg, A.3
Bowie, C.R.4
-
113
-
-
0025242104
-
The effect of serotonergic agents on haloperidol-induced catalepsy
-
Hicks P.B. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci. 47 (1990) 1609-1615
-
(1990)
Life Sci.
, vol.47
, pp. 1609-1615
-
-
Hicks, P.B.1
-
115
-
-
0033045962
-
A historical perspective of clozapine
-
Hippius H. A historical perspective of clozapine. J. Clin. Psychiatry 60 Suppl. 12 (1999) 22-23
-
(1999)
J. Clin. Psychiatry
, vol.60
, Issue.SUPPL. 12
, pp. 22-23
-
-
Hippius, H.1
-
116
-
-
0030439221
-
Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization
-
Iyer R.N., and Bradberry C.W. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J. Pharmacol. Exp. Ther. 277 (1996) 40-47
-
(1996)
J. Pharmacol. Exp. Ther.
, vol.277
, pp. 40-47
-
-
Iyer, R.N.1
Bradberry, C.W.2
-
117
-
-
0019152171
-
Rotational behaviour elicited by 5-HT in the rat: evidence for an inhibitory role of 5-HT in the substantia nigra and corpus striatum
-
James T.A., and Starr M.S. Rotational behaviour elicited by 5-HT in the rat: evidence for an inhibitory role of 5-HT in the substantia nigra and corpus striatum. J. Pharm. Pharmacol. 32 (1980) 196-200
-
(1980)
J. Pharm. Pharmacol.
, vol.32
, pp. 196-200
-
-
James, T.A.1
Starr, M.S.2
-
118
-
-
33644817011
-
2C receptors suppresses behavioral responses induced by drugs of abuse
-
2C receptors suppresses behavioral responses induced by drugs of abuse. Nat. Med. 12 (2006) 324-329
-
(2006)
Nat. Med.
, vol.12
, pp. 324-329
-
-
Ji, S.P.1
Zhang, Y.2
Van Cleemput, J.3
Jiang, W.4
Liao, M.5
Li, L.6
Wan, Q.7
Backstrom, J.R.8
Zhang, X.9
-
119
-
-
0023812652
-
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
-
Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45 (1988) 789-796
-
(1988)
Arch. Gen. Psychiatry
, vol.45
, pp. 789-796
-
-
Kane, J.1
Honigfeld, G.2
Singer, J.3
Meltzer, H.4
-
120
-
-
33748336475
-
Tardive dyskinesia circa 2006
-
Kane J.M. Tardive dyskinesia circa 2006. Am. J. Psychiatry 163 (2006) 1316-1318
-
(2006)
Am. J. Psychiatry
, vol.163
, pp. 1316-1318
-
-
Kane, J.M.1
-
121
-
-
0036007937
-
3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat
-
3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. Psychopharmacology (Berl.) 159 (2002) 341-350
-
(2002)
Psychopharmacology (Berl.)
, vol.159
, pp. 341-350
-
-
Kankaanpaa, A.1
Meririnne, E.2
Seppala, T.3
-
122
-
-
0029988896
-
Serotonin-dopamine interaction and its relevance to schizophrenia
-
Kapur S., and Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 153 (1996) 466-476
-
(1996)
Am. J. Psychiatry
, vol.153
, pp. 466-476
-
-
Kapur, S.1
Remington, G.2
-
123
-
-
0035660215
-
2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient
-
2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 50 (2001) 873-883
-
(2001)
Biol. Psychiatry
, vol.50
, pp. 873-883
-
-
Kapur, S.1
Remington, G.2
-
124
-
-
0029026941
-
2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study
-
2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 57 (1995) 103-107
-
(1995)
Life Sci.
, vol.57
, pp. 103-107
-
-
Kapur, S.1
Remington, G.2
Zipursky, R.B.3
Wilson, A.A.4
Houle, S.5
-
125
-
-
0035094264
-
2 receptor explain the action of atypical antipsychotics? A new hypothesis
-
2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry 158 (2001) 360-369
-
(2001)
Am. J. Psychiatry
, vol.158
, pp. 360-369
-
-
Kapur, S.1
Seeman, P.2
-
126
-
-
0034025771
-
2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia
-
2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
-
(2000)
Am. J. Psychiatry
, vol.157
, pp. 514-520
-
-
Kapur, S.1
Zipursky, R.2
Jones, C.3
Remington, G.4
Houle, S.5
-
129
-
-
0032982714
-
2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
-
2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156 (1999) 286-293
-
(1999)
Am. J. Psychiatry
, vol.156
, pp. 286-293
-
-
Kapur, S.1
Zipursky, R.B.2
Remington, G.3
-
130
-
-
33750631049
-
A longitudinal study of neurocognitive function in individuals at-risk for psychosis
-
Keefe R.S., Perkins D.O., Gu H., Zipursky R.B., Christensen B.K., and Lieberman J.A. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr. Res. 88 (2006) 26-35
-
(2006)
Schizophr. Res.
, vol.88
, pp. 26-35
-
-
Keefe, R.S.1
Perkins, D.O.2
Gu, H.3
Zipursky, R.B.4
Christensen, B.K.5
Lieberman, J.A.6
-
131
-
-
34648816582
-
2 receptor partial agonism?
-
2 receptor partial agonism?. Am. J. Psychiatry 164 (2007) 1310-1312
-
(2007)
Am. J. Psychiatry
, vol.164
, pp. 1310-1312
-
-
Kessler, R.M.1
-
132
-
-
33645229623
-
The factorial structure of the schedule for the deficit syndrome in schizophrenia
-
Kimhy D., Yale S., Goetz R.R., McFarr L.M., and Malaspina D. The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr. Bull. 32 (2006) 274-278
-
(2006)
Schizophr. Bull.
, vol.32
, pp. 274-278
-
-
Kimhy, D.1
Yale, S.2
Goetz, R.R.3
McFarr, L.M.4
Malaspina, D.5
-
134
-
-
33645241774
-
Subdomains within the negative symptoms of schizophrenia: commentary
-
Kirkpatrick B., and Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr. Bull. 32 (2006) 246-249
-
(2006)
Schizophr. Bull.
, vol.32
, pp. 246-249
-
-
Kirkpatrick, B.1
Fischer, B.2
-
136
-
-
0003530957
-
-
Krieger Publishing Co., Melbourne, FL. original published in 1919
-
Kraepelin E. Dementia Praecox and Paraphrenia. (1971), Krieger Publishing Co., Melbourne, FL. original published in 1919
-
(1971)
Dementia Praecox and Paraphrenia.
-
-
Kraepelin, E.1
-
137
-
-
33645221984
-
Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim
-
Laughren T., and Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull. 32 (2006) 220-222
-
(2006)
Schizophr. Bull.
, vol.32
, pp. 220-222
-
-
Laughren, T.1
Levin, R.2
-
138
-
-
0038107717
-
6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine
-
6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol. Biochem. Behav. 75 (2003) 281-288
-
(2003)
Pharmacol. Biochem. Behav.
, vol.75
, pp. 281-288
-
-
Leng, A.1
Ouagazzal, A.2
Feldon, J.3
Higgins, G.A.4
-
139
-
-
0029806639
-
Movement disorders associated with the serotonin selective reuptake inhibitors
-
Leo R.J. Movement disorders associated with the serotonin selective reuptake inhibitors. J. Clin. Psychiatry 57 (1996) 449-454
-
(1996)
J. Clin. Psychiatry
, vol.57
, pp. 449-454
-
-
Leo, R.J.1
-
140
-
-
0036161972
-
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials
-
Leucht S., Pitschel-Walz G., Engel R.R., and Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 159 (2002) 180-190
-
(2002)
Am. J. Psychiatry
, vol.159
, pp. 180-190
-
-
Leucht, S.1
Pitschel-Walz, G.2
Engel, R.R.3
Kissling, W.4
-
141
-
-
0038582771
-
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis
-
Leucht S., Wahlbeck K., Hamann J., and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (2003) 1581-1589
-
(2003)
Lancet
, vol.361
, pp. 1581-1589
-
-
Leucht, S.1
Wahlbeck, K.2
Hamann, J.3
Kissling, W.4
-
142
-
-
0036308284
-
Schizophrenia as a disorder of neurodevelopment
-
Lewis D.A., and Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25 (2002) 409-432
-
(2002)
Annu. Rev. Neurosci.
, vol.25
, pp. 409-432
-
-
Lewis, D.A.1
Levitt, P.2
-
143
-
-
40449123512
-
CATIE and CUtLASS: can we handle the truth?
-
Lewis S., and Lieberman J. CATIE and CUtLASS: can we handle the truth?. Br. J. Psychiatry 192 (2008) 161-163
-
(2008)
Br. J. Psychiatry
, vol.192
, pp. 161-163
-
-
Lewis, S.1
Lieberman, J.2
-
144
-
-
0032821589
-
Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective
-
Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry 46 (1999) 729-739
-
(1999)
Biol. Psychiatry
, vol.46
, pp. 729-739
-
-
Lieberman, J.A.1
-
145
-
-
0037199768
-
2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner
-
2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947 (2002) 157-165
-
(2002)
Brain Res.
, vol.947
, pp. 157-165
-
-
Liegeois, J.F.1
Ichikawa, J.2
Meltzer, H.Y.3
-
147
-
-
0033842215
-
Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated
-
Lucas G., De Deurwaerdere P., Porras G., and Spampinato U. Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated. Neuropharmacology 39 (2000) 1984-1995
-
(2000)
Neuropharmacology
, vol.39
, pp. 1984-1995
-
-
Lucas, G.1
De Deurwaerdere, P.2
Porras, G.3
Spampinato, U.4
-
148
-
-
0033621576
-
2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum
-
2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 74 (2000) 693-701
-
(2000)
J. Neurochem.
, vol.74
, pp. 693-701
-
-
Lucas, G.1
Spampinato, U.2
-
149
-
-
33748531860
-
Drug initiatives to improve cognitive function
-
Marder S.R. Drug initiatives to improve cognitive function. J. Clin. Psychiatry 67 Suppl. 9 (2006) 31-35
-
(2006)
J. Clin. Psychiatry
, vol.67
, Issue.SUPPL. 9
, pp. 31-35
-
-
Marder, S.R.1
-
150
-
-
39049178348
-
Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness
-
Marder S.R. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. J. Clin. Psychiatry 67 Suppl. 9 (2006) e03
-
(2006)
J. Clin. Psychiatry
, vol.67
, Issue.SUPPL. 9
-
-
Marder, S.R.1
-
151
-
-
0028342655
-
Risperidone in the treatment of schizophrenia
-
Marder S.R., and Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151 (1994) 825-835
-
(1994)
Am. J. Psychiatry
, vol.151
, pp. 825-835
-
-
Marder, S.R.1
Meibach, R.C.2
-
152
-
-
33847421275
-
Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development
-
Marek G.J. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development. Int. Rev. Neurobiol. 78 (2007) 165-192
-
(2007)
Int. Rev. Neurobiol.
, vol.78
, pp. 165-192
-
-
Marek, G.J.1
-
153
-
-
33845876953
-
2C receptor-selective agonist with preclinical antipsychotic-like activity
-
2C receptor-selective agonist with preclinical antipsychotic-like activity. J. Pharmacol. Exp. Ther. 320 (2007) 486-496
-
(2007)
J. Pharmacol. Exp. Ther.
, vol.320
, pp. 486-496
-
-
Marquis, K.L.1
Sabb, A.L.2
Logue, S.F.3
Brennan, J.A.4
Piesla, M.J.5
Comery, T.A.6
Grauer, S.M.7
Ashby Jr., C.R.8
Nguyen, H.Q.9
Dawson, L.A.10
Barrett, J.E.11
Stack, G.12
Meltzer, H.Y.13
Harrison, B.L.14
Rosenzweig-Lipson, S.15
-
155
-
-
85047698267
-
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
-
McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., and Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 (2006) 600-610
-
(2006)
Am. J. Psychiatry
, vol.163
, pp. 600-610
-
-
McEvoy, J.P.1
Lieberman, J.A.2
Stroup, T.S.3
Davis, S.M.4
Meltzer, H.Y.5
Rosenheck, R.A.6
Swartz, M.S.7
Perkins, D.O.8
Keefe, R.S.9
Davis, C.E.10
Severe, J.11
Hsiao, J.K.12
-
158
-
-
0002629884
-
Atypical antipsychotic drugs
-
Kupfer D., and Bloom F.E. (Eds), Raven Press, New York, NY
-
Meltzer H. Atypical antipsychotic drugs. In: Kupfer D., and Bloom F.E. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York, NY 1277-1286
-
(1995)
Psychopharmacology: The Fourth Generation of Progress
, pp. 1277-1286
-
-
Meltzer, H.1
-
162
-
-
0020040075
-
Disruption of primate social behavior by D-amphetamine and cocaine: differential antagonism by antipsychotics
-
Miczek K.A., and Yoshimura H. Disruption of primate social behavior by D-amphetamine and cocaine: differential antagonism by antipsychotics. Psychopharmacology (Berl.) 76 (1982) 163-171
-
(1982)
Psychopharmacology (Berl.)
, vol.76
, pp. 163-171
-
-
Miczek, K.A.1
Yoshimura, H.2
-
166
-
-
0035077696
-
2A receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study
-
2A receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study. Synapse 40 (2004) 102-112
-
(2004)
Synapse
, vol.40
, pp. 102-112
-
-
Minabe, Y.1
Hashimoto, K.2
Watanabe, K.I.3
Ashby, C.R.Jr.4
-
167
-
-
4344693762
-
2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex
-
2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 29 (2004) 1637-1647
-
(2004)
Neuropsychopharmacology
, vol.29
, pp. 1637-1647
-
-
Mirjana, C.1
Baviera, M.2
Invernizzi, R.W.3
Balducci, C.4
-
168
-
-
12344326514
-
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
-
Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10 (2005) 79-104
-
(2005)
Mol. Psychiatry
, vol.10
, pp. 79-104
-
-
Miyamoto, S.1
Duncan, G.E.2
Marx, C.E.3
Lieberman, J.A.4
-
169
-
-
0019188610
-
From motivation to action: functional interface between the limbic system and the motor system
-
Mogenson G.J., Jones D.L., and Yim C.Y. From motivation to action: functional interface between the limbic system and the motor system. Prog. Neurobiol. 14 (1980) 69-97
-
(1980)
Prog. Neurobiol.
, vol.14
, pp. 69-97
-
-
Mogenson, G.J.1
Jones, D.L.2
Yim, C.Y.3
-
170
-
-
0023155574
-
Interactions between prolactin and dopaminergic neurons
-
Moore K.E. Interactions between prolactin and dopaminergic neurons. Biol. Reprod. 36 (1987) 47-58
-
(1987)
Biol. Reprod.
, vol.36
, pp. 47-58
-
-
Moore, K.E.1
-
171
-
-
0033214515
-
Chronic clozapine, but not haloperidol, alters the response of mesoprefrontal dopamine neurons to stress and clozapine challenges in rats
-
Morrow B.A., Rosenberg S.J., and Roth R.H. Chronic clozapine, but not haloperidol, alters the response of mesoprefrontal dopamine neurons to stress and clozapine challenges in rats. Synapse 34 (1999) 28-35
-
(1999)
Synapse
, vol.34
, pp. 28-35
-
-
Morrow, B.A.1
Rosenberg, S.J.2
Roth, R.H.3
-
172
-
-
0842286591
-
2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum
-
2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum. Neuropsychopharmacology 29 (2004) 319-326
-
(2004)
Neuropsychopharmacology
, vol.29
, pp. 319-326
-
-
Navailles, S.1
De Deurwaerdere, P.2
Porras, G.3
Spampinato, U.4
-
174
-
-
0035134050
-
7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression
-
7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. J. Chem. Neuroanat. 21 (2001) 63-73
-
(2001)
J. Chem. Neuroanat.
, vol.21
, pp. 63-73
-
-
Neumaier, J.F.1
Sexton, T.J.2
Yracheta, J.3
Diaz, A.M.4
Brownfield, M.5
-
175
-
-
34347336444
-
Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics
-
Newman-Tancredi A., Cussac D., and Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr. Opin. Investig. Drugs 8 (2007) 539-554
-
(2007)
Curr. Opin. Investig. Drugs
, vol.8
, pp. 539-554
-
-
Newman-Tancredi, A.1
Cussac, D.2
Depoortere, R.3
-
178
-
-
6344256332
-
1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels
-
1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. J. Pharmacol. Exp. Ther. 311 (2004) 711-719
-
(2004)
J. Pharmacol. Exp. Ther.
, vol.311
, pp. 711-719
-
-
O'Dell, L.E.1
Parsons, L.H.2
-
179
-
-
3242790211
-
Effects of serotonin-dopamine antagonists on prepulse inhibition and neurotransmitter contents in the rat cortex
-
Ojima T., Ito C., Sakurai E., Sakurai E., Watanabe T., and Yanai K. Effects of serotonin-dopamine antagonists on prepulse inhibition and neurotransmitter contents in the rat cortex. Neurosci. Lett. 366 (2004) 130-134
-
(2004)
Neurosci. Lett.
, vol.366
, pp. 130-134
-
-
Ojima, T.1
Ito, C.2
Sakurai, E.3
Sakurai, E.4
Watanabe, T.5
Yanai, K.6
-
180
-
-
24344436398
-
Structural brain imaging evidence for multiple pathological processes at different stages ofbrain development in schizophrenia
-
Pantelis C., Yucel M., Wood S.J., Velakoulis D., Sun D., Berger G., Stuart G.W., Yung A., Phillips L., and McGorry P.D. Structural brain imaging evidence for multiple pathological processes at different stages ofbrain development in schizophrenia. Schizophr. Bull. 31 (2005) 672-696
-
(2005)
Schizophr. Bull.
, vol.31
, pp. 672-696
-
-
Pantelis, C.1
Yucel, M.2
Wood, S.J.3
Velakoulis, D.4
Sun, D.5
Berger, G.6
Stuart, G.W.7
Yung, A.8
Phillips, L.9
McGorry, P.D.10
-
181
-
-
28444455645
-
1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia
-
1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia. Pharmacol. Biochem. Behav. 82 (2005) 361-372
-
(2005)
Pharmacol. Biochem. Behav.
, vol.82
, pp. 361-372
-
-
Park, W.K.1
Jeong, D.2
Cho, H.3
Lee, S.J.4
Cha, M.Y.5
Pae, A.N.6
Choi, K.I.7
Koh, H.Y.8
Kong, J.Y.9
-
182
-
-
0033560989
-
1B/1A receptor agonist, potentiates cocaine-induced increases in nucleus accumbens dopamine
-
1B/1A receptor agonist, potentiates cocaine-induced increases in nucleus accumbens dopamine. Synapse 32 (1999) 132-135
-
(1999)
Synapse
, vol.32
, pp. 132-135
-
-
Parsons, L.H.1
Koob, G.F.2
Weiss, F.3
-
185
-
-
0029938033
-
Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects
-
Peacock L., Solgaard T., Lublin H., and Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl.) 124 (1996) 188-196
-
(1996)
Psychopharmacology (Berl.)
, vol.124
, pp. 188-196
-
-
Peacock, L.1
Solgaard, T.2
Lublin, H.3
Gerlach, J.4
-
187
-
-
30544447091
-
Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice
-
Pires J.G., Bonikovski V., and Futuro-Neto H.A. Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz. J. Med. Biol. Res. 38 (2005) 1867-1872
-
(2005)
Braz. J. Med. Biol. Res.
, vol.38
, pp. 1867-1872
-
-
Pires, J.G.1
Bonikovski, V.2
Futuro-Neto, H.A.3
-
190
-
-
0036886022
-
4 receptors selectively regulate the impulse-dependent exocytosis of dopamine in the rat striatum: in vivo studies with morphine, amphetamine and cocaine
-
4 receptors selectively regulate the impulse-dependent exocytosis of dopamine in the rat striatum: in vivo studies with morphine, amphetamine and cocaine. Neuropharmacology 43 (2002) 1099-1109
-
(2002)
Neuropharmacology
, vol.43
, pp. 1099-1109
-
-
Porras, G.1
Di Matteo, V.2
De Deurwaerdere, P.3
Esposito, E.4
Spampinato, U.5
-
191
-
-
0036008435
-
2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum
-
2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26 (2002) 311-324
-
(2002)
Neuropsychopharmacology
, vol.26
, pp. 311-324
-
-
Porras, G.1
Di Matteo, V.2
Fracasso, C.3
Lucas, G.4
De Deurwaerdere, P.5
Caccia, S.6
Esposito, E.7
Spampinato, U.8
-
192
-
-
0036314871
-
2C receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex
-
2C receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J. Neurochem. 82 (2002) 93-100
-
(2002)
J. Neurochem.
, vol.82
, pp. 93-100
-
-
Pozzi, L.1
Acconcia, S.2
Ceglia, I.3
Invernizzi, R.W.4
Samanin, R.5
-
193
-
-
34147160638
-
Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis
-
Pukrop R., Ruhrmann S., Schultze-Lutter F., Bechdolf A., Brockhaus-Dumke A., and Klosterkotter J. Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophr. Res. 92 (2007) 116-125
-
(2007)
Schizophr. Res.
, vol.92
, pp. 116-125
-
-
Pukrop, R.1
Ruhrmann, S.2
Schultze-Lutter, F.3
Bechdolf, A.4
Brockhaus-Dumke, A.5
Klosterkotter, J.6
-
194
-
-
0034084299
-
In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia
-
Raedler T.J., Knable M.B., Jones D.W., Lafargue T., Urbina R.A., Egan M.F., Pickar D., and Weinberger D.R. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 23 (2000) 56-68
-
(2000)
Neuropsychopharmacology
, vol.23
, pp. 56-68
-
-
Raedler, T.J.1
Knable, M.B.2
Jones, D.W.3
Lafargue, T.4
Urbina, R.A.5
Egan, M.F.6
Pickar, D.7
Weinberger, D.R.8
-
196
-
-
0141455897
-
Understanding antipsychotic "atypicality": a clinical and pharmacological moving target
-
Remington G. Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J. Psychiatry Neurosci. 28 (2003) 275-284
-
(2003)
J. Psychiatry Neurosci.
, vol.28
, pp. 275-284
-
-
Remington, G.1
-
197
-
-
33846837063
-
Tardive dyskinesia: eliminated, forgotten, or overshadowed?
-
Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed?. Curr. Opin. Psychiatry 20 (2007) 131-137
-
(2007)
Curr. Opin. Psychiatry
, vol.20
, pp. 131-137
-
-
Remington, G.1
-
198
-
-
0032934615
-
2 receptor effects of antipsychotics: bridging basic and clinical findings using PET
-
2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J. Clin. Psychiatry 60 Suppl. 10 (1999) 15-19
-
(1999)
J. Clin. Psychiatry
, vol.60
, Issue.SUPPL. 10
, pp. 15-19
-
-
Remington, G.1
Kapur, S.2
-
199
-
-
0033983417
-
Atypical antipsychotics: are some more atypical than others?
-
Remington G., and Kapur S. Atypical antipsychotics: are some more atypical than others?. Psychopharmacology (Berl.) 148 (2000) 3-15
-
(2000)
Psychopharmacology (Berl.)
, vol.148
, pp. 3-15
-
-
Remington, G.1
Kapur, S.2
-
200
-
-
31344459099
-
Augmentation strategies in treatment-resistant schizophrenia
-
Remington G., Saha A., Chong S.A., and Shammi C. Augmentation strategies in treatment-resistant schizophrenia. CNS Drugs 19 (2005) 843-872
-
(2005)
CNS Drugs
, vol.19
, pp. 843-872
-
-
Remington, G.1
Saha, A.2
Chong, S.A.3
Shammi, C.4
-
202
-
-
1542313966
-
Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder
-
Robinson D.G., Woerner M.G., McMeniman M., Mendelowitz A., and Bilder R.M. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161 (2004) 473-479
-
(2004)
Am. J. Psychiatry
, vol.161
, pp. 473-479
-
-
Robinson, D.G.1
Woerner, M.G.2
McMeniman, M.3
Mendelowitz, A.4
Bilder, R.M.5
-
205
-
-
0001792366
-
The role of serotonin in schizophrenia
-
Bloom F.E., and Kupfer D. (Eds), Raven Press, Ltd., New York, NY
-
Roth B.L., and Meltzer H.Y. The role of serotonin in schizophrenia. In: Bloom F.E., and Kupfer D. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, Ltd., New York, NY 1215-1227
-
(1995)
Psychopharmacology: The Fourth Generation of Progress
, pp. 1215-1227
-
-
Roth, B.L.1
Meltzer, H.Y.2
-
207
-
-
0030071335
-
Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia
-
Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 7 (1996) 3-23
-
(1996)
Behav. Pharmacol.
, vol.7
, pp. 3-23
-
-
Sams-Dodd, F.1
-
209
-
-
34447095484
-
Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications
-
Savina I., and Beninger R.J. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications. Schizophr. Res. 94 (2007) 128-138
-
(2007)
Schizophr. Res.
, vol.94
, pp. 128-138
-
-
Savina, I.1
Beninger, R.J.2
-
211
-
-
0028176861
-
2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine
-
2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 62 (1994) 1382-1389
-
(1994)
J. Neurochem.
, vol.62
, pp. 1382-1389
-
-
Schmidt, C.J.1
Sullivan, C.K.2
Fadayel, G.M.3
-
212
-
-
0027468102
-
Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task
-
Schultz W., Apicella P., and Ljungberg T. Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task. J. Neurosci. 13 (1993) 900-913
-
(1993)
J. Neurosci.
, vol.13
, pp. 900-913
-
-
Schultz, W.1
Apicella, P.2
Ljungberg, T.3
-
213
-
-
0036221550
-
Atypical antipsychotics: mechanism of action
-
Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47 (2002) 27-38
-
(2002)
Can. J. Psychiatry
, vol.47
, pp. 27-38
-
-
Seeman, P.1
-
214
-
-
50349091629
-
Dopamine receptors, schizophrenia and antipsychotics
-
Seeman P. Dopamine receptors, schizophrenia and antipsychotics. Can. J. Diagn. January (2006) 1-7
-
(2006)
Can. J. Diagn.
, Issue.January
, pp. 1-7
-
-
Seeman, P.1
-
215
-
-
0017068246
-
Antipsychotic drug doses and neuroleptic/dopamine receptors
-
Seeman P., Lee T., Chau-Wong M., and Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261 (1976) 717-719
-
(1976)
Nature
, vol.261
, pp. 717-719
-
-
Seeman, P.1
Lee, T.2
Chau-Wong, M.3
Wong, K.4
-
216
-
-
33746575616
-
2high dopamine receptors
-
2high dopamine receptors. Synapse 60 (2006) 319-346
-
(2006)
Synapse
, vol.60
, pp. 319-346
-
-
Seeman, P.1
Schwarz, J.2
Chen, J.F.3
Szechtman, H.4
Perreault, M.5
McKnight, G.S.6
Roder, J.C.7
Quirion, R.8
Boksa, P.9
Srivastava, L.K.10
Yanai, K.11
Weinshenker, D.12
Sumiyoshi, T.13
-
217
-
-
0031953450
-
2 receptors, yet occupy high levels of these receptors
-
2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry 3 (1998) 123-134
-
(1998)
Mol. Psychiatry
, vol.3
, pp. 123-134
-
-
Seeman, P.1
Tallerico, T.2
-
218
-
-
0032973806
-
2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
-
2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. J. Psychiatry 156 (1999) 876-884
-
(1999)
Am. J. Psychiatry
, vol.156
, pp. 876-884
-
-
Seeman, P.1
Tallerico, T.2
-
219
-
-
34247538931
-
Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis
-
Sepehry A.A., Potvin S., Elie R., and Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J. Clin. Psychiatry 68 (2007) 604-610
-
(2007)
J. Clin. Psychiatry
, vol.68
, pp. 604-610
-
-
Sepehry, A.A.1
Potvin, S.2
Elie, R.3
Stip, E.4
-
220
-
-
35748959361
-
Social cognition and neurocognition: effects of risperidone, olanzapine, and haloperidol
-
Sergi M.J., Green M.F., Widmark C., Reist C., Erhart S., Braff D.L., Kee K.S., Marder S.R., and Mintz J. Social cognition and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am. J. Psychiatry 164 (2007) 1585-1592
-
(2007)
Am. J. Psychiatry
, vol.164
, pp. 1585-1592
-
-
Sergi, M.J.1
Green, M.F.2
Widmark, C.3
Reist, C.4
Erhart, S.5
Braff, D.L.6
Kee, K.S.7
Marder, S.R.8
Mintz, J.9
-
221
-
-
33846605009
-
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms
-
Sergi M.J., Rassovsky Y., Widmark C., Reist C., Erhart S., Braff D.L., Marder S.R., and Green M.F. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr. Res. 90 (2007) 316-324
-
(2007)
Schizophr. Res.
, vol.90
, pp. 316-324
-
-
Sergi, M.J.1
Rassovsky, Y.2
Widmark, C.3
Reist, C.4
Erhart, S.5
Braff, D.L.6
Marder, S.R.7
Green, M.F.8
-
222
-
-
33846327871
-
2C agonist, shows activity in animal models of antipsychotic activity
-
2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52 (2007) 279-290
-
(2007)
Neuropharmacology
, vol.52
, pp. 279-290
-
-
Siuciak, J.A.1
Chapin, D.S.2
McCarthy, S.A.3
Guanowsky, V.4
Brown, J.5
Chiang, P.6
Marala, R.7
Patterson, T.8
Seymour, P.A.9
Swick, A.10
Iredale, P.A.11
-
223
-
-
0029101173
-
Novel dopamine receptor subtypes as targets for antipsychotic drugs
-
Sokoloff P., Diaz J., Levesque D., Pilon C., Dimitriadou V., Griffon N., Lammers C.H., Martres M.P., and Schwartz J.C. Novel dopamine receptor subtypes as targets for antipsychotic drugs. Ann. N. Y. Acad. Sci. 757 (1995) 278-292
-
(1995)
Ann. N. Y. Acad. Sci.
, vol.757
, pp. 278-292
-
-
Sokoloff, P.1
Diaz, J.2
Levesque, D.3
Pilon, C.4
Dimitriadou, V.5
Griffon, N.6
Lammers, C.H.7
Martres, M.P.8
Schwartz, J.C.9
-
225
-
-
0033768430
-
[(123)I]-epidepride single photon emission tomography (SPET) study
-
[(123)I]-epidepride single photon emission tomography (SPET) study. Br. J. Psychiatry 177 (2000) 408-415
-
(2000)
Br. J. Psychiatry
, vol.177
, pp. 408-415
-
-
Stephenson, C.M.1
Bigliani, V.2
Jones, H.M.3
Mulligan, R.S.4
Acton, P.D.5
Visvikis, D.6
Ell, P.J.7
Kerwin, R.W.8
Pilowsky, L.S.9
-
226
-
-
34250628858
-
2A/2C receptors
-
2A/2C receptors. Eur. J. Pharmacol. 564 (2007) 123-130
-
(2007)
Eur. J. Pharmacol.
, vol.564
, pp. 123-130
-
-
Su, Y.A.1
Si, T.M.2
Zhou, D.F.3
Guo, C.M.4
Wang, X.D.5
Yang, Y.6
Shu, L.7
Liang, J.H.8
-
227
-
-
40349103296
-
Schizophrenia genetics: the search for a hard lead
-
Sullivan P.F. Schizophrenia genetics: the search for a hard lead. Curr. Opin. Psychiatry 21 (2008) 157-160
-
(2008)
Curr. Opin. Psychiatry
, vol.21
, pp. 157-160
-
-
Sullivan, P.F.1
-
228
-
-
0036202379
-
Partial dopamine agonists in the treatment of psychosis
-
Tamminga C.A. Partial dopamine agonists in the treatment of psychosis. J. Neural Transm. 109 (2002) 411-420
-
(2002)
J. Neural Transm.
, vol.109
, pp. 411-420
-
-
Tamminga, C.A.1
-
229
-
-
0028989953
-
3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex
-
3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology (Berl.) 119 (1995) 15-19
-
(1995)
Psychopharmacology (Berl.)
, vol.119
, pp. 15-19
-
-
Tanda, G.1
Frau, R.2
Di Chiara, G.3
-
231
-
-
0029816246
-
Serotonergic modulation of strata D2 dopamine receptor binding in humans measured with positron emission tomography
-
Tiihonen J., Kuoppamaki M., Nagren K., Bergman J., Eronen E., Syvalahti E., and Hietala J. Serotonergic modulation of strata D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology (Berl.) 126 (1996) 277-280
-
(1996)
Psychopharmacology (Berl.)
, vol.126
, pp. 277-280
-
-
Tiihonen, J.1
Kuoppamaki, M.2
Nagren, K.3
Bergman, J.4
Eronen, E.5
Syvalahti, E.6
Hietala, J.7
-
234
-
-
0002600739
-
The significance of dopamine-receptor blockade for the action of neuroleptic drugs
-
Coyle J., Brill H., Deniker P., Hippius H., and Bradley P.B. (Eds), Excerptica Medica, Amsterdam
-
Van Rossum J. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Coyle J., Brill H., Deniker P., Hippius H., and Bradley P.B. (Eds). Neuropsychopharmacology, Proceedings of the 5th Collegium Internationale Neuro-psychopharmacologicum (CINP) (1967), Excerptica Medica, Amsterdam 321-329
-
(1967)
Neuropsychopharmacology, Proceedings of the 5th Collegium Internationale Neuro-psychopharmacologicum (CINP)
, pp. 321-329
-
-
Van Rossum, J.1
-
235
-
-
33646709186
-
Schizophrenia: who is at risk? Who is a case?
-
Verdoux H., and Cougnard A. Schizophrenia: who is at risk? Who is a case?. Int. Clin. Psychopharmacol. 21 Suppl. 2 (2006) S17-S19
-
(2006)
Int. Clin. Psychopharmacol.
, vol.21
, Issue.SUPPL. 2
-
-
Verdoux, H.1
Cougnard, A.2
-
236
-
-
0037212448
-
2 receptor binding, mood, and attentiveness in humans: a replication study
-
2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol. Biochem. Behav. 74 (2003) 425-432
-
(2003)
Pharmacol. Biochem. Behav.
, vol.74
, pp. 425-432
-
-
Verhoeff, N.P.1
Christensen, B.K.2
Hussey, D.3
Lee, M.4
Papatheodorou, G.5
Kopala, L.6
Rui, Q.7
Zipursky, R.B.8
Kapur, S.9
-
239
-
-
33750626892
-
Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia - findings from an in vivo SPECT study
-
Voruganti L.N., and Awad A.G. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia - findings from an in vivo SPECT study. Schizophr Res. 88 (2006) 179-186
-
(2006)
Schizophr Res.
, vol.88
, pp. 179-186
-
-
Voruganti, L.N.1
Awad, A.G.2
-
240
-
-
0031953485
-
Neurodevelopmental and neuroprogressive processes in schizophrenia. Antithetical or complementary, over a lifetime trajectory of disease?
-
Waddington J.L., Lane A., Scully P.J., Larkin C., and O'Callaghan E. Neurodevelopmental and neuroprogressive processes in schizophrenia. Antithetical or complementary, over a lifetime trajectory of disease?. Psychiatr. Clin. N. Am. 21 (1998) 123-149
-
(1998)
Psychiatr. Clin. N. Am.
, vol.21
, pp. 123-149
-
-
Waddington, J.L.1
Lane, A.2
Scully, P.J.3
Larkin, C.4
O'Callaghan, E.5
-
241
-
-
0026701850
-
Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat
-
Wadenberg M.L. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J. Neural Transm. Gen. Sect. 89 (1992) 49-59
-
(1992)
J. Neural Transm. Gen. Sect.
, vol.89
, pp. 49-59
-
-
Wadenberg, M.L.1
-
242
-
-
0018398866
-
Serotonin-dopamine interactions in the nigrostriatal system
-
Waldmeier P.C., and Delini-Stula A.A. Serotonin-dopamine interactions in the nigrostriatal system. Eur. J. Pharmacol. 55 (1979) 363-373
-
(1979)
Eur. J. Pharmacol.
, vol.55
, pp. 363-373
-
-
Waldmeier, P.C.1
Delini-Stula, A.A.2
-
243
-
-
0036689288
-
Risk factors and the neurodevelopmental course of schizophrenia
-
Walker E. Risk factors and the neurodevelopmental course of schizophrenia. Eur. Psychiatry 17 (2002) 363-369
-
(2002)
Eur. Psychiatry
, vol.17
, pp. 363-369
-
-
Walker, E.1
-
244
-
-
0023215296
-
Implications of normal brain development for the pathogenesis of schizophrenia
-
Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44 (1987) 660-669
-
(1987)
Arch. Gen. Psychiatry
, vol.44
, pp. 660-669
-
-
Weinberger, D.R.1
-
245
-
-
0023918477
-
Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism
-
Weinberger D.R., Berman K.F., and Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry 45 (1988) 609-615
-
(1988)
Arch. Gen. Psychiatry
, vol.45
, pp. 609-615
-
-
Weinberger, D.R.1
Berman, K.F.2
Illowsky, B.P.3
-
247
-
-
0000358118
-
A biochemical and pharmacological suggestion about certain mental disorders
-
Woolley D.W., and Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. U.S.A. 40 (1954) 228-231
-
(1954)
Proc. Natl. Acad. Sci. U.S.A.
, vol.40
, pp. 228-231
-
-
Woolley, D.W.1
Shaw, E.2
-
248
-
-
0035104045
-
2 dopamine receptor blockade by amisulpride in schizophrenia
-
2 dopamine receptor blockade by amisulpride in schizophrenia. J. Clin. Psychopharmacol. 21 (2001) 207-214
-
(2001)
J. Clin. Psychopharmacol.
, vol.21
, pp. 207-214
-
-
Xiberas, X.1
Martinot, J.L.2
Mallet, L.3
Artiges, E.4
Canal, M.5
Loc'h, C.6
Maziere, B.7
Paillere-Martinot, M.L.8
-
250
-
-
0029037007
-
Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra
-
Yamamoto B.K., Nash J.F., and Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 273 (1995) 1063-1070
-
(1995)
J. Pharmacol. Exp. Ther.
, vol.273
, pp. 1063-1070
-
-
Yamamoto, B.K.1
Nash, J.F.2
Gudelsky, G.A.3
-
251
-
-
33745451845
-
1A agonist with antipsychotic- and antiparkinsonian-like properties
-
1A agonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology 51 (2006) 129-140
-
(2006)
Neuropharmacology
, vol.51
, pp. 129-140
-
-
Zazpe, A.1
Artaiz, I.2
Innerarity, A.3
Del Olmo, E.4
Castro, E.5
Labeaga, L.6
Pazos, A.7
Orjales, A.8
-
252
-
-
0034285086
-
Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
-
Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., and Bymaster F.P. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23 (2000) 250-262
-
(2000)
Neuropsychopharmacology
, vol.23
, pp. 250-262
-
-
Zhang, W.1
Perry, K.W.2
Wong, D.T.3
Potts, B.D.4
Bao, J.5
Tollefson, G.D.6
Bymaster, F.P.7
|